These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 1892433)
1. [Pharmacokinetics of amphotericin B and its derivatives]. Vetkina IF Antibiot Khimioter; 1991 Apr; 36(4):36-8. PubMed ID: 1892433 [No Abstract] [Full Text] [Related]
5. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Bellmann R; Egger P; Wiedermann CJ Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850 [No Abstract] [Full Text] [Related]
6. Antifungal agents--clinical pharmacokinetics and drug interactions. Lipp HP Mycoses; 2008; 51 Suppl 1():7-18. PubMed ID: 18471156 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children]. Jullien V Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286 [TBL] [Abstract][Full Text] [Related]
8. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Lewis RE; Wiederhold NP Clin Infect Dis; 2003 Sep; 37(6):871-2. PubMed ID: 12955666 [No Abstract] [Full Text] [Related]
9. Lipid complexes of amphotericin B: the competitive picture. Richardson MD J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817 [No Abstract] [Full Text] [Related]
10. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Wasan KM; Conklin JS Clin Infect Dis; 1997 Jan; 24(1):78-80. PubMed ID: 8994768 [No Abstract] [Full Text] [Related]
11. Drug therapy of systemic fungal infections, Part II. Gross M N C Med J; 1984 Sep; 45(9):551-3. PubMed ID: 6592453 [No Abstract] [Full Text] [Related]
12. The experience is CLEAR. Chandrasekar P Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248 [TBL] [Abstract][Full Text] [Related]
13. [Choice and use of antifungal drugs]. Dupont B Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672 [TBL] [Abstract][Full Text] [Related]
14. Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha. Hoeprich PD; Flynn NM; Kawachi MM; Lee KK; Lawrence RM; Heath LK; Schaffner CP Ann N Y Acad Sci; 1988; 544():517-46. PubMed ID: 3214091 [TBL] [Abstract][Full Text] [Related]
15. Lipid formulations of amphotericin B. Dix SP; Andriole VT Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516 [TBL] [Abstract][Full Text] [Related]
16. [Commonly used antifungal agents in the treatment of systemic mycoses]. Berenguer Berenguer J Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308 [No Abstract] [Full Text] [Related]
17. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment. Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189 [No Abstract] [Full Text] [Related]
18. [Amphotericin B: the end of an era]. Oude Lashof AM; Kullberg BJ Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a polyene antifungal agent, liposomal amphotericin B (L-AMB), in a severely burned patient. Sasaki J; Matsumoto K; Fujishima S; Morita K; Hori S J Chemother; 2014 Oct; 26(5):312-4. PubMed ID: 24070023 [No Abstract] [Full Text] [Related]
20. Liposomal formulations of amphotericin B: differences according to the scientific evidence. Azanza JR; Sádada B; Reis J Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]